Pharm-Chem Exchange|

|Suppliers Directory|

 |Technology Market| huabiao

Pharm-Chem Info|

|Market News|

|Join us|

 cpcn3.jpg (4492 bytes)
mark1.jpg (2235 bytes) cpcn4.jpg (3951 bytes)

1. China's DSD Acid Over-Supply
DSD acid is an important intermediate used in detergents, paper production, textile dyeing. In 1993, there are about 20 factories in China produce DSD acid with capacity of 4000 tons per year. In 1998 , there are 50 factories with production capacity over 16000 tons per year. Actual production quantity in 1998 is around 7100 - 7300 tons. In 1999, 1/3 of the factories have to stop the production due to low demand and over supply in the market.
2. China's Fine Chemical Industry To Be Adjusted
It is reported that China's fine chemical industry has a low production value which takes only 35% .It needs the development of high technology and adjustment of its product structure.
3. Production Situation Of Beta Naphthol In China
Beta Naphthol (2-Naphthol) is a very important dyestuff intermediate. It is widely used in acid dyes, mordant dyes, active dyes, Naphthol dyes, organic pigments and specialty chemicals. It is also used in pharmaceutical, agrochemical and rubber industries.
Currently, the world total production capacity of beta Naphthol is around 100 thousand metric tons per year . China, India , Japan, Italy and some east European countries are the main production countries . In Japan there are three production factories with the total capacity of 10 thousand metric tons per year. India has 7 factories of beta Naphthol production with the capacity of 10 thousand metric tons per year . Italy has one factory with capacity of 20 thousand metric tons per year. In former Russia , the production capacity is around 14 thousand metric tons per year. Czech? capacity is 5000 thousand per year, Iran's capacity is 2 thousand per year. In China, the production capacity has reached 40 thousand metric tons per year. In the past, Germany's capacity was 12 thousand metric tons per year and United States had the capacity over 18 thousand metric tons per year. In recent years, the actual production quantity is around 80 thousand per year in the world.
Germany and United States have stopped their production due to heavy pollution. China and India are the main exporters to these countries.
There are about 10 factories in China producing Beta Naphthol. China's production capacity changes like this: 15.778 thousand tons in the year of 1986 ; 20.863 thousand tons in the year of 1991; 25.760 thousand tons in the year of 1992 ; 27.892 thousand tons in the year of 1993 ; 32.312 thousand tons in the year of 1994; 33 thousand tons in the year of 1995.
The price of beta naphthol has experienced ups-and-downs within 10 years.
4. 12 Fine Chemical Production Bases To Be Set Up
In order to fasten the development of fine chemical industries, China decides to set up 12 fine chemical production bases respectively in the following areas: Wuxi , Suzhou, Nantong, Huangyan, Shashi, Xiangtan, Deyang, Wuhu, Fushun, Xinji, Binzhou and Luzhou.
5. BIRD Grant To Enzo Biochem For Hepatitis B Study Expansion
Farmingdale, NY, 1/12/00 (CSI) - Enzo Biochem, Inc. has reported that they have received a grant from the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD) for human clinical trial expansion using Enzo's proprietary immune modulation technology for hepatitis B virus (HBV) patients. BIRD is a foundation funded by Israel, and U.S. Projects are approved by the BIRD Board of Governors with grant proposal review by the Office of the Chief Scientist of Israel's Ministry of Trade and Industry and the U.S. National Institute of Standards and Technology. The immune modulation technology uses oral administration of specific hepatitis B proteins to control HBV anti-viral immune response. HBV does not destroy the liver cells it infects, but the body's immune response to HBV results dies, and thus Enzo immune modulation technology may be able to control the complication caused by the body's immune response to HBV. Enzo Biochem develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and provides medical diagnostic services to the medical community.
6. Phase II Clinical Program In Prostate Cancer Initiated By Cephalon
West Chester, PA, 1/12/00 (CSI) - Cephalon, Inc. has reported initiation of their Phase II clinical program for CEP-701 oral therapy to investigate its ability to slow tumor growth. In pre-clinical models of prostate cancer, CEP-701 was shown to slow tumor growth. TAP Holdings Inc. is Cephalon's clinical partner in the Phase II prostate cancer patient program. Cephalon, Inc. discovers, develops and markets pharmaceutical products for neurological disorders and cancer treatment.